Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.
Feijóo-Bandín S, Aragón-Herrera A, Rodríguez-Penas D, Portolés M, Roselló-Lletí E, Rivera M, González-Juanatey JR, Lago F. Feijóo-Bandín S, et al. Front Physiol. 2017 Aug 18;8:599. doi: 10.3389/fphys.2017.00599. eCollection 2017. Front Physiol. 2017. PMID: 28868039 Free PMC article. Review.
Metabolic alterations derived from absence of Two-Pore Channel 1 at cardiac level.
Garcia-Rua V, Feijoo-Bandin S, Garcia-Vence M, Aragon-Herrera A, Bravo SB, Rodriguez-Penas D, Mosquera-Leal A, Lear PV, Parrington J, Alonso J, Rosello-Lleti E, Portoles M, Rivera M, Gonzalez-Juanatey JR, Lago F. Garcia-Rua V, et al. J Biosci. 2016 Dec;41(4):643-658. doi: 10.1007/s12038-016-9647-4. J Biosci. 2016. PMID: 27966485
Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue.
Aragón-Herrera A, Feijóo-Bandín S, Abella V, Álvarez L, Roselló-Lletí E, Portolés M, Tarazón E, Bigazzi M, Bani D, Gualillo O, González-Juanatey JR, Lago F. Aragón-Herrera A, et al. Pharmacol Res. 2019 Jun;144:51-65. doi: 10.1016/j.phrs.2019.04.009. Epub 2019 Apr 5. Pharmacol Res. 2019. PMID: 30954631
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
Aragón-Herrera A, Feijóo-Bandín S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, Costa Pereira TM, García-Caballero T, Rodríguez-Segade S, Rodríguez J, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, González-Juanatey JR, Lago F. Aragón-Herrera A, et al. Biochem Pharmacol. 2019 Dec;170:113677. doi: 10.1016/j.bcp.2019.113677. Epub 2019 Oct 21. Biochem Pharmacol. 2019. PMID: 31647926
Adipokines and Inflammation: Focus on Cardiovascular Diseases.
Feijóo-Bandín S, Aragón-Herrera A, Moraña-Fernández S, Anido-Varela L, Tarazón E, Roselló-Lletí E, Portolés M, Moscoso I, Gualillo O, González-Juanatey JR, Lago F. Feijóo-Bandín S, et al. Int J Mol Sci. 2020 Oct 18;21(20):7711. doi: 10.3390/ijms21207711. Int J Mol Sci. 2020. PMID: 33081064 Free PMC article. Review.
Relaxin has beneficial effects on liver lipidome and metabolic enzymes.
Aragón-Herrera A, Feijóo-Bandín S, Moraña-Fernández S, Anido-Varela L, Roselló-Lletí E, Portolés M, Tarazón E, Lage R, Moscoso I, Barral L, Bani D, Bigazzi M, Gualillo O, González-Juanatey JR, Lago F. Aragón-Herrera A, et al. FASEB J. 2021 Jul;35(7):e21737. doi: 10.1096/fj.202002620RR. FASEB J. 2021. PMID: 34143495
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.
Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, Moraña-Fernández S, Campos-Toimil M, García-Caballero T, Barral L, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, Moscoso I, Lage R, González-Juanatey JR, Feijóo-Bandín S, Lago F. Aragón-Herrera A, et al. Front Pharmacol. 2022 Feb 2;13:827033. doi: 10.3389/fphar.2022.827033. eCollection 2022. Front Pharmacol. 2022. PMID: 35185578 Free PMC article.
Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases.
Aragón-Herrera A, Feijóo-Bandín S, Anido-Varela L, Moraña-Fernández S, Roselló-Lletí E, Portolés M, Tarazón E, Gualillo O, González-Juanatey JR, Lago F. Aragón-Herrera A, et al. J Pers Med. 2022 Jun 21;12(7):1021. doi: 10.3390/jpm12071021. J Pers Med. 2022. PMID: 35887517 Free PMC article. Review.
21 results